GlassScriptPhysician profile
Aimee A Oliver
NPI 1306823505
$2,796.49
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $216 · 2020: $214 · 2021: $819 · 2022: $1,066 · 2023: $431 · 2024: $50.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $482.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $482.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $432.74 | 2020-2023 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $392.28 | 2019-2023 | Qulipta, Vraylar, Ubrelvy |
| Lilly USA, LLC | $330.27 | 2021-2023 | Mounjaro, Jardiance, Emgality |
| Esperion Therapeutics, INC. | $319.26 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $195.88 | 2019-2023 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $174.04 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $169.79 | 2022 | |
| Ibsa Pharma INC. | $125.54 | 2019-2022 | |
| Eisai INC. | $98.21 | 2019-2021 | |
| Amgen INC. | $86.13 | 2020-2021 | |
| Amarin Pharma, INC. | $68.71 | 2020-2021 | |
| Hologic Sales and Service, LLC | $57.23 | 2022 | |
| Galderma Laboratories, L.P. | $50.76 | 2024 | |
| Nestle Healthcare Nutrition INC. | $36.06 | 2021 | |
| Alfasigma USA, INC. | $35.01 | 2020-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $24.44 | 2023 | Shingrix |
| Idorsia Pharmaceuticals US INC | $21.99 | 2022 | |
| Antares Pharma, INC. | $20.54 | 2023 | Xyosted, Nocdurna, Tlando |
| Azurity Pharmaceuticals, INC. | $17.17 | 2023 | Horizant |
| Strongbridge US INC. | $16.74 | 2020 | |
| Halozyme INC | $16.41 | 2023 | |
| Acella Pharmaceuticals, LLC | $16.20 | 2023 | NP Thyroid 60 |
| Nabriva Therapeutics, Plc | $14.83 | 2022 | |
| Bausch Health US, LLC | $13.56 | 2019 | |
| Currax Pharmaceuticals LLC | $13.35 | 2022 | |
| Shield Therapeutics INC | $13.28 | 2023 | Accrufer |
| Nalpropion Pharmaceuticals LLC | $12.67 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.95 | 2021 | |
| Vistapharm, INC. | $11.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aimee Oliver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.